Kalber Tammy L, Smith Christopher J, Howe Franklyn A, Griffiths John R, Ryan Anderson J, Waterton John C, Robinson Simon P
Division of Basic Medical Sciences, St. George's, University of London, London, UK.
Invest Radiol. 2005 Dec;40(12):784-91. doi: 10.1097/01.rli.0000188025.66872.e4.
The objective of this study was to investigate the duration of R2* and R2 enhancement in murine liver in vivo after administration of a single dose of 3 different iron oxide-based contrast agents.
Murine liver R2* and R2 were quantified longitudinally postadministration of 2.5 mgFe/kg ferumoxides, 2.5 mgFe/kg ferumoxytol, 2.5 or 5 mgFe/kg feruglose, or saline over 50 days. Changes in R2* and R2 were evaluated histologically using Perl's staining and by atomic absorption spectrometry.
All 3 contrast agents significantly increased liver R2* and R2 4 hours after challenge. After 10 days, R2* and R2 for both the ferumoxides and ferumoxytol cohorts had recovered to saline control levels, whereas the faster R2* and R2 of the feruglose cohort was sustained and significantly faster than control at day 50. Histology revealed feruglose in both Kupffer and endothelial cells, whereas both ferumoxides and ferumoxytol were associated with the Kupffer cells.
Compared with ferumoxides and ferumoxytol, feruglose exhibits prolonged R2* and R2 enhancement of murine liver.
本研究的目的是调查单次给予3种不同的基于氧化铁的造影剂后，小鼠肝脏体内R2*和R2增强的持续时间。
在给予2.5mgFe/kg菲立磁、2.5mgFe/kg ferumoxytol、2.5或5mgFe/kg feruglose或生理盐水后，对小鼠肝脏R2和R2进行长达50天的纵向定量分析。使用Perl氏染色和原子吸收光谱法对R2和R2的变化进行组织学评估。
所有3种造影剂在注入后4小时均显著增加肝脏R2和R2。10天后，菲立磁组和ferumoxytol组的R2和R2均恢复到生理盐水对照水平，而feruglose组更快的R2*和R2持续存在，且在第50天时显著快于对照组。组织学检查显示，feruglose存在于库普弗细胞和内皮细胞中，而菲立磁和ferumoxytol均与库普弗细胞有关。
与菲立磁和ferumoxytol相比，feruglose对小鼠肝脏的R2*和R2增强作用持续时间更长。
